Почетна › Рак дојке › Северна Каролина
Kliničke studije za Рак дојке u državi Северна Каролина
91 studija za Рак дојке traži učesnike na lokacijama u državi Северна Каролина.
Gradovi u državi Северна Каролина
- Durham63 студија
- Charlotte22 студија
- Winston-Salem15 студија
- Shelby5 студија
- Concord5 студија
- Gastonia4 студија
- Greenville4 студија
- High Point4 студија
- Cary3 студија
- Asheville3 студија
- Greensboro3 студија
- Raleigh3 студија
Zvanični tekst studije (na engleskom)
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07360314Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Duke University Medical Center, Durham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05696626PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07069595A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Atrium Health, Charlotte
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05894239A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology, Cary
Тражи се учесникФаза 1
Узраст од 18 до 55 · Жене · Ажурирано 12. 11. 2026. · NCT07310420Utility of a Mobile Application for Young Women With Breast Cancer
- Atrium Health Levine Cancer, Charlotte
Тражи се учесник
Узраст од 18 до 45 · Жене · Ажурирано 12. 11. 2026. · NCT07009093ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Duke Cancer Institute, Durham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07007559A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Duke Cancer Institute, Durham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT03424005The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
Тражи се учесникЗдраве особе су добродошле
Узраст од 45 до 75 · Оба пола · Ажурирано 6. 11. 2026. · NCT06995898Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
- UNC Cancer Hospital, Chapel Hill
Тражи се учесник
Узраст 18 и старији · Жене · Ажурирано 5. 11. 2026. · NCT07389967Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Atrium Levine Cancer Institute, Charlotte
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07214532Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Duke Cancer Institute, Durham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT05315700A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Messino Cancer Centers, Asheville
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology, Cary
- University of North Carolina Medical Center, Chapel Hill
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Novant Health Cancer Institute, Charlotte
- Duke Cancer Institute, Durham
- Novant Health Cancer Institute, Winston-Salem
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- и још 16
Тражи се учесникФаза 3
Узраст од 18 до 50 · Оба пола · Ажурирано 4. 11. 2026. · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of North Carolina Medical Center, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 4. 11. 2026. · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- и још 6
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- и још 21
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213791Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07059884Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- и још 47
Тражи се учесникФаза 3
Узраст од 18 до 60 · Жене · Ажурирано 4. 11. 2026. · NCT05879926Radiation Therapy and Thymus Function in Young Women With Breast Cancer
- Duke Cancer Center, Durham
Тражи се учесникОпсервациона студија
Узраст од 18 до 50 · Жене · Ажурирано 4. 11. 2026. · NCT07725172A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Novant Health Cancer Institute ( Site 0019), Charlotte
- Novant Health Oncology Specialists ( Site 0074), Winston-Salem
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07060807The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Levine Cancer Institute, Albemarle
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
- и још 11
Тражи се учесникФаза 3
Узраст 60 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06377852ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Oncology Specialists of Charlotte Pa, Charlotte
- Carolina Oncology Specialists, Charlotte
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07173751A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
- Levine Cancer, Charlotte
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT07102381EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Atrium Health Levine Cancer Institute, Charlotte
- Novant Health Cancer Institute - Elizabeth, Charlotte
- FirstHealth Outpatient Cancer Center, Pinehurst
- и још 2
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06401421Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- Comprehensive Cancer Center at Wake Forest University (CCCWFU), Winston-Salem
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT02422641A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Levine Cancer Institute, Charlotte
- Novant Health Cancer Institute, Charlotte
- Novant Health Oncology Specialists, Winston-Salem
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07100106UNC Pleural Fluid Registry
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT05620329A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Wake Forest Baptist Hematology and Oncology - Clemmons, Clemmons
- Atrium Health Wake Forest Baptist, Winston-Salem
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07062965Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
- Duke Cancer Institute, Durham
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06774027Weight Management After Cancer for Survivors in Rural Communities
- Duke University Medical Center, Durham
- Maria Parham Cancer Center, Henderson
- Scotland Health, Laurinburg
- и још 2
Тражи се учесник
Узраст 18 и старији · Жене · Ажурирано 16. 10. 2026. · NCT07426952BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Duke Cancer Center, Durham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT06120283Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- Duke University/Duke Cancer Center, Durham
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07140172A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Levine Cancer Institute ( Site 0014), Charlotte
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06312176A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- Research Site, Winston-Salem
Тражи се учесникФаза 3
Узраст од 18 до 130 · Оба пола · Ажурирано 13. 10. 2026. · NCT05774951A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Charlotte
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT05123482Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06993844Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial
- Wake Forest NCORP RB, Winston-Salem
Тражи се учесник
Узраст од 18 до 85 · Оба пола · Ажурирано 6. 10. 2026. · NCT07474090Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.